A vaccine built for a different strain is now being tested directly against the one actually killing people — with no other option currently available
The Democratic Republic of Congo has begun receiving 70,000 doses of the Ervebo Ebola vaccine, the World Health Organization confirmed Thursday, in an emergency deployment aimed at slowing what health officials have described as the fastest-spreading Ebola outbreak on record — even though the vaccine was never originally designed to fight the specific strain currently circulating.
The allocation
The doses arrived following a formal request last week from the DRC government to the International Coordinating Group on Vaccine Provision (ICG), which manages the global Ebola vaccine stockpile. The ICG approved an immediate initial release on Monday, split into two distinct uses: 20,000 doses will go toward a Phase 3 clinical trial specifically designed to determine whether Ervebo offers meaningful protection against the Bundibugyo strain of Ebola virus disease, while the remaining 50,000 doses will be prioritized for frontline and health workers, in line with current recommendations from the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE).
Why this matters: a vaccine mismatch
The core complication is that Ervebo is licensed and proven effective specifically against the Zaire strain of Ebola — the species responsible for most historical outbreaks, including West Africa’s catastrophic 2014–2016 epidemic. It has never been formally evaluated for effectiveness in humans against Bundibugyo virus, the rarer, related species currently driving the DRC’s outbreak. As of this writing, there remains no vaccine or specific treatment approved anywhere for the Bundibugyo strain — meaning this deployment represents a calculated emergency gamble rather than a proven solution.
That gamble is not without scientific basis. WHO officials say early laboratory and animal studies suggest Ervebo may offer some degree of cross-protection against Bundibugyo virus, and it is that preliminary evidence the Phase 3 trial is now designed to confirm — or disprove — in humans, at scale, for the first time. It is not yet known whether that protection will actually hold.
A parallel, faster-than-usual research effort
This vaccine deployment is not occurring in isolation. Trials for the first-ever Bundibugyo species-specific candidate vaccine — as opposed to a repurposed Zaire-strain vaccine like Ervebo — began in the United Kingdom on July 24, with a second trial launching in Canada shortly afterward. According to Dr. Vasee Moorthy, acting lead of WHO’s R&D Blueprint, trials for this outbreak began unusually quickly compared to past Ebola responses, because clinical protocols had already been written before the current outbreak was even declared in mid-May — a rare instance of pandemic-preparedness planning paying off in real time. A new 100-bed treatment centre has also been inaugurated in Bunia, the capital of Ituri province and the epicentre of the outbreak, and clinical trials of treatment options are separately rolling out in the same province.
The scale of the crisis this is responding to
WHO Director-General Tedros Adhanom Ghebreyesus, who called the vaccine allocation “an important example of global solidarity in action,” has separately confirmed the outbreak has now surpassed 5,000 cases and more than 2,300 deaths across six provinces since being declared on May 15 — making it, by his own account, the second-largest Ebola outbreak ever recorded. The response continues to be significantly complicated by fragile health infrastructure and ongoing armed conflict across the affected regions of eastern DRC, factors that have hampered vaccine and treatment delivery even as the scientific tools to fight the virus slowly begin to catch up with the outbreak itself.
Since the ICG’s Ebola vaccine mechanism was established in 2021, more than 56,000 Ervebo doses have already been allocated to DRC outbreaks specifically, with a further 167,000 doses used in preventive campaigns for health and frontline workers across DRC, Guinea-Bissau, Kenya, Sierra Leone and Uganda — underscoring both the scale of the region’s recurring exposure to Ebola and the well-established emergency delivery infrastructure now being mobilized once again, this time against a strain the system was never originally built to fight.
